⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 8, 2024Open Access

Table S4 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors

Caroline E. Dravillas Samuel S. Coleman Rebecca Hoyd Griffin Caryotakis Louis Denko Carlos H.F. Chan Michelle L. Churchman Nicholas Denko Rebecca D. Dodd Islam Eljilany Sheetal Hardikar Marium Husain Alexandra P. Ikeguchi Ning Jin Qin Ma Martin D. McCarter Afaf E.G. Osman Lary A. Robinson Eric A. Singer Gabriel Tinoco Cornelia M. Ulrich Yousef Zakharia Daniel Spakowicz Ahmad A. Tarhini Aik Choon Tan

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Modeling results for the microbes enriched in the tumors responsive or not-responsive to immunotherapy

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dravillas et al. (2024) studied this question.

synapsesocial.com/papers/68e5d116b6db6435875674ff https://doi.org/10.1158/2767-9764.26519590

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S4 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
2Table S2 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
3Table S2 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
4Figure S4 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
5Table S3 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024

Table S3 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
Table S1 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
Table S1 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024